Want to see SYRE full AI Analyst Report?

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

563 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SYRE Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Spyre

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SYRE Stock 12 Month Forecast

Average Price Target

$101.50

▲(39.02% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Spyre Therapeutics in the last 3 months. The average price target is $101.50 with a high forecast of $135.00 and a low forecast of $80.00. The average price target represents a 39.02% change from the last price of $73.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","75":"$75","136":"$136","44.5":"$44.5","105.5":"$105.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,44.5,75,105.5,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.54,75.49846153846154,80.45692307692309,85.41538461538462,90.37384615384616,95.3323076923077,100.29076923076923,105.24923076923078,110.20769230769231,115.16615384615385,120.1246153846154,125.08307692307693,130.04153846153847,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.54,72.92153846153846,75.30307692307693,77.68461538461538,80.06615384615385,82.44769230769231,84.82923076923078,87.21076923076923,89.5923076923077,91.97384615384615,94.35538461538462,96.73692307692308,99.11846153846153,{"y":101.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.54,71.26769230769231,71.99538461538462,72.72307692307693,73.45076923076924,74.17846153846155,74.90615384615384,75.63384615384615,76.36153846153846,77.08923076923077,77.81692307692308,78.54461538461538,79.27230769230769,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.4,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.49,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.46,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$101.50

Lowest Price Target$80.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

06/23/26

Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity

David Hoang

Deutsche Bank

$115→$135

Buy

84.91%

Upside

Reiterated

06/23/26

Spyre Therapeutics price target raised to $135 from $115 at Deutsche BankSpyre Therapeutics price target raised to $135 from $115 at Deutsche Bank

Alex Thompson CFA

Stifel Nicolaus

$107

Buy

46.56%

Upside

Reiterated

06/22/26

Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)

Debanjana Chatterjee

JonesTrading

$95→$104

Buy

42.45%

Upside

Assigned

06/16/26

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)

David Nierengarten

Wedbush

$80→$100

Buy

36.97%

Upside

Reiterated

06/16/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and Tyra Bioscience (NASDAQ: TYRA)

Akash Tewari

Jefferies

$95→$98

Buy

34.23%

Upside

Reiterated

06/16/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Spyre Therapeutics (NASDAQ: SYRE)

Julian Harrison

BTIG

$98→$112

Buy

53.40%

Upside

Reiterated

06/15/26

Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation

Sam Slutsky

LifeSci Capital

$103

Buy

41.08%

Upside

Reiterated

06/15/26

Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

06/03/26

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$115

Buy

57.51%

Upside

Reiterated

05/06/26

Guggenheim Remains a Buy on Spyre Therapeutics (SYRE)

Samantha Semenkow

Citi

$64→$97

Buy

32.86%

Upside

Assigned

05/06/26

Spyre Therapeutics price target raised to $97 from $64 at CitiSpyre Therapeutics price target raised to $97 from $64 at Citi

Yanan Zhu

Wells Fargo

$50→$90

Buy

23.27%

Upside

Assigned

04/14/26

Spyre Therapeutics price target raised to $90 from $50 at Wells FargoSpyre Therapeutics price target raised to $90 from $50 at Wells Fargo

Joseph Catanzaro

Mizuho Securities

$53→$84

Buy

15.05%

Upside

Reiterated

04/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alfresa Holdings (Other OTC: ARHCF), Spyre Therapeutics (NASDAQ: SYRE) and Eisai Co (Other OTC: ESALF)

Colleen M. Kusy

Robert W. Baird

$65→$90

Buy

23.27%

Upside

Reiterated

04/14/26

Spyre Therapeutics price target raised to $90 from $65 at BairdSpyre Therapeutics price target raised to $90 from $65 at Baird

Thomas Smith

Leerink Partners

$49→$106

Buy

45.19%

Upside

Reiterated

04/13/26

Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

06/23/26

Tyler Van Buren Initiates Buy on Spyre Therapeutics, Citing Best‑in‑Class IBD Potential and $30B Rheumatology Opportunity

David Hoang

Deutsche Bank

$115→$135

Buy

84.91%

Upside

Reiterated

06/23/26

Spyre Therapeutics price target raised to $135 from $115 at Deutsche BankSpyre Therapeutics price target raised to $135 from $115 at Deutsche Bank

Alex Thompson CFA

Stifel Nicolaus

$107

Buy

46.56%

Upside

Reiterated

06/22/26

Stifel Nicolaus Remains a Buy on Spyre Therapeutics (SYRE)

Debanjana Chatterjee

JonesTrading

$95→$104

Buy

42.45%

Upside

Assigned

06/16/26

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)

David Nierengarten

Wedbush

$80→$100

Buy

36.97%

Upside

Reiterated

06/16/26

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE) and Tyra Bioscience (NASDAQ: TYRA)

Akash Tewari

Jefferies

$95→$98

Buy

34.23%

Upside

Reiterated

06/16/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Spyre Therapeutics (NASDAQ: SYRE)

Julian Harrison

BTIG

$98→$112

Buy

53.40%

Upside

Reiterated

06/15/26

Julian Harrison Reiterates Buy on Spyre Therapeutics, Lifts Price Target to $112 on Encouraging SPY002 Ulcerative Colitis Data and TL1A Platform Validation

Sam Slutsky

LifeSci Capital

$103

Buy

41.08%

Upside

Reiterated

06/15/26

Spyre Therapeutics: Buy Rating Reaffirmed as Positive SPY002 Ulcerative Colitis Data Supports $103 Price Target

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

06/03/26

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Vera Therapeutics (NASDAQ: VERA) and Spyre Therapeutics (NASDAQ: SYRE)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$115

Buy

57.51%

Upside

Reiterated

05/06/26

Guggenheim Remains a Buy on Spyre Therapeutics (SYRE)

Samantha Semenkow

Citi

$64→$97

Buy

32.86%

Upside

Assigned

05/06/26

Spyre Therapeutics price target raised to $97 from $64 at CitiSpyre Therapeutics price target raised to $97 from $64 at Citi

Yanan Zhu

Wells Fargo

$50→$90

Buy

23.27%

Upside

Assigned

04/14/26

Spyre Therapeutics price target raised to $90 from $50 at Wells FargoSpyre Therapeutics price target raised to $90 from $50 at Wells Fargo

Joseph Catanzaro

Mizuho Securities

$53→$84

Buy

15.05%

Upside

Reiterated

04/14/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alfresa Holdings (Other OTC: ARHCF), Spyre Therapeutics (NASDAQ: SYRE) and Eisai Co (Other OTC: ESALF)

Colleen M. Kusy

Robert W. Baird

$65→$90

Buy

23.27%

Upside

Reiterated

04/14/26

Spyre Therapeutics price target raised to $90 from $65 at BairdSpyre Therapeutics price target raised to $90 from $65 at Baird

Thomas Smith

Leerink Partners

$49→$106

Buy

45.19%

Upside

Reiterated

04/13/26

Analysts' Top Healthcare Picks: Oruka Therapeutics (ORKA), Spyre Therapeutics (SYRE)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Spyre Therapeutics

3 Months

Alex Thompson CFAStifel Nicolaus

Success Rate

10/15 ratings generated profit

Average Return

+29.13%

Copying Alex Thompson CFA's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +29.13% per trade.

1 Year

Alex Thompson CFAStifel Nicolaus

Success Rate

12/15 ratings generated profit

Average Return

+106.39%

Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +106.39% per trade.

2 Years

Julian HarrisonBTIG

Success Rate

20/20 ratings generated profit

Average Return

+248.96%

Copying Julian Harrison's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +248.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SYRE Analyst Recommendation Trends

Rating

Feb 26

Mar 26

Apr 26

May 26

Jun 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SYRE has received 49 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SYRE average Analyst price target in the past 3 months is 101.50.

Each month's total comprises the sum of three months' worth of ratings.

SYRE Financial Forecast

SYRE Earnings Forecast

Next quarter’s earnings estimate for SYRE is -$0.76 with a range of -$1.00 to -$0.49. The previous quarter’s EPS was -$0.74. SYRE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Sales Forecast

Next quarter’s sales forecast for SYRE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SYRE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SYRE has Performed in-line its overall industry.

SYRE Stock Forecast FAQ

What is SYRE’s average 12-month price target, according to analysts?

Based on analyst ratings, Spyre Therapeutics, Inc’s 12-month average price target is 101.50.

What is SYRE’s upside potential, based on the analysts’ average price target?

Spyre Therapeutics, Inc has 39.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SYRE a Buy, Sell or Hold?

Spyre Therapeutics, Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Spyre Therapeutics, Inc’s price target?

The average price target for Spyre Therapeutics, Inc is 101.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $80.00. The average price target represents 39.02% Increase from the current price of $73.01.

What do analysts say about Spyre Therapeutics, Inc?

Spyre Therapeutics, Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of SYRE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Spyre Therapeutics (SYRE) Stock Forecast & Price Target

SYRE Analyst Ratings

SYRE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Spyre Therapeutics

SYRE Analyst Recommendation Trends

SYRE Financial Forecast

SYRE Earnings Forecast

SYRE Sales Forecast

SYRE Stock Forecast FAQ

Detailed List of Analyst Forecasts